Triheptanoin
Dojolvi (triheptanoin) is a small molecule pharmaceutical. Triheptanoin was first approved as Dojolvi on 2020-06-30.
Download report
Favorite
FDA Novel Drug Approvals 2020
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
Dojolvi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triheptanoin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| DOJOLVI | Ultragenyx Pharmaceutical | N-213687 RX | 2020-06-30 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| dojolvi | New Drug Application | 2020-09-01 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRIHEPTANOIN, DOJOLVI, ULTRAGENYX PHARM INC | |||
| 2027-06-30 | ODE-311 | ||
| 2025-06-30 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
33 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glucose metabolism disorders | D044882 | 1 | 1 | — | — | — | 2 | ||
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | 1 | — | — | — | 2 |
| Job syndrome | D007589 | EFO_0003775 | D82.4 | 1 | 1 | — | — | — | 2 |
| Glycogen storage disease type v | D006012 | E74.04 | — | 2 | — | — | — | 2 | |
| Huntington disease | D006816 | G10 | — | 2 | — | — | — | 2 | |
| Ataxia telangiectasia | D001260 | Orphanet_100 | G11.3 | — | 1 | — | — | — | 1 |
| Glycogen storage disease type iii | D006010 | Orphanet_366 | E74.03 | — | 1 | — | — | — | 1 |
| Glycogen storage disease type vii | D006014 | E74.09 | — | 1 | — | — | — | 1 | |
| Igg deficiency | D017099 | D80.3 | — | 1 | — | — | — | 1 | |
| Rett syndrome | D015518 | F84.2 | — | 1 | — | — | — | 1 |
Show 2 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Glycogen storage disease type i | D005953 | Orphanet_364 | E74.01 | 1 | — | — | — | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemophilia b | D002836 | D67 | — | — | — | — | 1 | 1 | |
| Barth syndrome | D056889 | Orphanet_111 | E78.71 | — | — | — | — | 1 | 1 |
| Pyruvate carboxylase deficiency disease | D015324 | EFO_1001142 | E74.4 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | TRIHEPTANOIN |
| INN | triheptanoin |
| Description | Triheptanoin, sold under the brand name Dojolvi, is a medication for the treatment of children and adults with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD).
|
| Classification | Small molecule |
| Drug class | Glycerolipids |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCC(=O)OCC(COC(=O)CCCCCC)OC(=O)CCCCCC |
Identifiers
| PDB | — |
| CAS-ID | 620-67-7 |
| RxCUI | 1313234 |
| ChEMBL ID | CHEMBL4297585 |
| ChEBI ID | — |
| PubChem CID | 69286 |
| DrugBank | DB11677 |
| UNII ID | 2P6O7CFW5K (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 481 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
135 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more